Solid Biosciences is advancing genetic medicines to treat patients with neuromuscular and cardiac diseases. To create effective therapies, Solid has built a state-of-the-art process development and characterization lab to establish their transient transfection-based gene therapies. Solid’s pipeline includes SGT-003, a treatment for Duchenne muscular dystrophy and AVB-401, a treatment for BAG3-mediated dilated cardiomyopathy. As the programs progress, Solid will continue to refine their manufacturing process so that they can meet their goal of ensuring that no patient goes without therapy.

Solid Biosciences

Founded: 2013
Location: Cambridge, MA
Employee range: 50 - 200
Clinical stage: Clin0
Therapy area: DMD
Drug types: GEN, MUS, NEU, CVV, RAR
Lead product: SGT-003
Funding: $144M stock Mar 2021; $90M stock (PP) Dec 2020; $60M stock (PP) Jul 2019; $134M IPO Jan 2018

Drug notes:

About:

Jobs: